Ranitidine Hydrochloride



Ranitidine Hydrochloride





(ra nye’ te deen)

Apo-Ranitidine (CAN), CO Ranitidine (CAN), Gen-Ranitidine (CAN), Novo-Ranidine (CAN), Nu-Ranit (CAN), PMS-Ranitidine (CAN), ratio-Ranitidine (CAN), Zantac, Zantac EFFERdose, Zantac 75, Zantac 150

PREGNANCY CATEGORY B


Drug Classes

Gastric acid secretion inhibitor

Histamine-2 (H2) antagonist


Therapeutic Actions

Competitively inhibits the action of histamine at the H2 receptors of the parietal cells of the stomach, inhibiting basal gastric acid secretion and gastric acid secretion that is stimulated by food, insulin, histamine, cholinergic agonists, gastrin, and pentagastrin.


Indications



  • Short-term treatment of active duodenal ulcer


  • Maintenance therapy for duodenal ulcer at reduced dosage


  • Short-term treatment and maintenance therapy of active, benign gastric ulcer


  • Short-term treatment of GERD


  • Pathologic hypersecretory conditions (eg, Zollinger-Ellison syndrome) (adults only)


  • Treatment and maintenance of healing of erosive esophagitis


  • Treatment of heartburn, acid indigestion, sour stomach



Available Forms

Tablets—75, 150, 300 mg; capsules—150, 300 mg; effervescent tablets—150 mg; syrup—15 mg/mL; oral solution—15 mg/mL; injection—25 mg/mL


Dosages

Adults

Jul 21, 2016 | Posted by in NURSING | Comments Off on Ranitidine Hydrochloride

Full access? Get Clinical Tree

Get Clinical Tree app for offline access